DelveInsight’s “Allergic Conjunctivitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Allergic Conjunctivitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Allergic Conjunctivitis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Allergic Conjunctivitis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Allergic Conjunctivitis: An Overview
Allergic conjunctivitis (AC) is an inflammation of the conjunctiva (a thin membrane covering the white part of the eye) due to allergy. It is often interchangeably known as Ocular Allergy; a common immunological hypersensitivity disorder.
Allergic conjunctivitis is a bilateral and self-limiting inflammatory process, fundamentally caused by an IgE-mediated immune mechanism or immediate hypersensitivity mechanism resulting from direct contact of the allergen with the conjunctival surface in sensitized patients – triggering mast cell activation and the release of different mediators.
Allergic conjunctivitis can affect both children and adults, often coexisting with other allergic diseases such as asthma, atopic dermatitis, or food allergy, though it is particularly associated with allergic rhinitis. Indeed, the term “rhinoconjunctivitis” is used in joint reference to both disorders, thereby complicating knowledge of each individual disease condition.
Allergic Conjunctivitis Market Key Facts
-
According to American Association for Pediatric Ophthalmology and Strabismus (AAPOS), Allergic conjunctivitis is a common eye condition that affects more than 20% of the population.
-
According to the European Academy of Allergy and Clinical Immunology (EAACI), the most common form is acute and seasonal conjunctivitis (SAC). It is often associated with rhinitis and affects mainly children and young adults. 14.6% of European children aged 13 to 14 are affected. The least rare is vernal keratoconjunctivitis (VKC). It accounts for 3.2 per 10,000 individuals in Western Europe.
Allergic Conjunctivitis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Allergic Conjunctivitis pipeline therapies. It also thoroughly assesses the Allergic Conjunctivitis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Allergic Conjunctivitis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Allergic Conjunctivitis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Allergic Conjunctivitis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Allergic Conjunctivitis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Allergic Conjunctivitis Epidemiology, Segmented as –
-
Total Prevalent Cases of Allergic Conjunctivitis in the 7MM (2019–2032)
-
Diagnosed and Treated Cases of Allergic Conjunctivitis in 7MM (2019–2032)
-
Type-specific cases of Allergic Conjunctivitis in the 7MM (2019–2032)
-
Gender-specific cases of Allergic Conjunctivitis in the 7MM (2019–2032)
Allergic Conjunctivitis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Allergic Conjunctivitis market or expected to be launched during the study period. The analysis covers the Allergic Conjunctivitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Allergic Conjunctivitis drugs based on their sale and market share.
The report also covers the Allergic Conjunctivitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Allergic Conjunctivitis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Allergic Conjunctivitis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/allergic-conjunctivitis-market
Allergic Conjunctivitis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Allergic Conjunctivitis. Currently, Aldeyra Therapeutics is leading the therapeutics market with its Allergic Conjunctivitis drug candidates in the most advanced stage of clinical development.
Allergic Conjunctivitis Companies Actively Working in the Therapeutics Market Include
Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Inc., Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina España S.A, Biomay AG, and many others.
Emerging and Marketed Allergic Conjunctivitis Therapies Covered in the Report Include:
-
Reproxalap: Aldeyra Therapeutics
-
VSJ-110: Vanda Pharmaceuticals
-
OK-101: Okyo Pharma
-
Dextenza: Ocular Therapeutix
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/allergic-conjunctivitis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Allergic Conjunctivitis Competitive Intelligence Analysis
4. Allergic Conjunctivitis Market Overview at a Glance
5. Allergic Conjunctivitis Disease Background and Overview
6. Allergic Conjunctivitis Patient Journey
7. Allergic Conjunctivitis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Allergic Conjunctivitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Allergic Conjunctivitis Unmet Needs
10. Key Endpoints of Allergic Conjunctivitis Treatment
11. Allergic Conjunctivitis Marketed Therapies
12. Allergic Conjunctivitis Emerging Drugs and Latest Therapeutic Advances
13. Allergic Conjunctivitis Seven Major Market Analysis
14. Attribute Analysis
15. Allergic Conjunctivitis Market Outlook (In US, EU5, and Japan)
16. Allergic Conjunctivitis Companies Active in the Market
17. Allergic Conjunctivitis Access and Reimbursement Overview
18. KOL Views on the Allergic Conjunctivitis Market
19. Allergic Conjunctivitis Market Drivers
20. Allergic Conjunctivitis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/allergic-conjunctivitis-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Papilloma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Papilloma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Papilloma market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/